Drug makers must share patent info with government

Congress file s2658-119, before Congress. Still to be decided as of 2026-07-28.

Latest action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 528.

What it does

Drug makers must report patent details to two agencies When a company applies to sell a new drug, it must now tell both the FDA and the patent office the same facts about patents for that drug, with a signed promise the information matches.

The bigger picture

Patent challenges could become easier to win in court If a drug company fails to share required patent information, someone can use that mistake as a defense if sued for patent infringement, making it easier to challenge weak patents in court.

What to watch

New rule applies only to drugs filed after the law passes Drugs already approved before this law takes effect are only covered for new patents filed later, so older medicines keep the old rules.

Official summary

This bill requires applicants seeking approval of a drug or licensure of a biological product to submit certain information about relevant patents to both the Food and Drug Administration (FDA) and the U.S. Patent and Trademark Office (USPTO).Specifically, the bill requires applicants to make certifications and disclosures related to each applicable patent on a proposed drug or biological product. An applicable patent is a patent or patent application held or sought by the applicant for the drug or biological product (including a formulation or composition, method of use, or method of manufacturing).For each applicable patent, an applicant must submit to the USPTO any information material to patentability that the applicant submitted to the FDA and any information provided by the FDA in response. The applicant must certify that this submission is complete and consistent with the information the applicant provided to the FDA.Further, for each applicable patent, an applicant must certify that certain information submitted to the FDA is consistent with information the applicant provided to the USPTO. This is specific to statements or characterizations that are material to patentabilit

Read the official record for s2658-119

See everything up for a vote · This week in Congress · See what we have filed with the clerk